James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Federal Funds Rate Unchanged: What Does It Mean for Investors?

The Federal Reserve didn't raise the federal funds rate, though there's almost certainly one coming in December. Should we have just bitten the bullet now?

10 Super-High-Growth Stocks to Buy Now

Few investors were looking for growth stocks to buy in the shadow of interest rate uncertainty. But now, it's EXACTLY the right time to go shopping.

RAD Stock: Rite Aid Is Buy-Worthy on the Rest of the Earnings Story

A disappointing Rite Aid earnings report sent RAD stock sharply lower, but that selloff is actually a buying opportunity into a surprisingly solid company.

Why Amicus Therapeutics, Inc. (FOLD), Sprint Corp (S) and FedEx Corporation (FDX) Are 3 of Today’s Worst Stocks

Hump day was forgettable for Amicus Therapeutics (FOLD), Sprint (S) and FedEx (FDX). This is what traders need to know.

PayPal Stock: PYPL Deals Back Into Online Gambling

Owners of PayPal stock were treated to a compelling surprise this week, though a closer look at the numbers elicits a mere "meh."